JP2011528332A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528332A5
JP2011528332A5 JP2011517954A JP2011517954A JP2011528332A5 JP 2011528332 A5 JP2011528332 A5 JP 2011528332A5 JP 2011517954 A JP2011517954 A JP 2011517954A JP 2011517954 A JP2011517954 A JP 2011517954A JP 2011528332 A5 JP2011528332 A5 JP 2011528332A5
Authority
JP
Japan
Prior art keywords
human beta
beta defensin
composition
seq
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/059251 external-priority patent/WO2010007165A2/en
Publication of JP2011528332A publication Critical patent/JP2011528332A/ja
Publication of JP2011528332A5 publication Critical patent/JP2011528332A5/ja
Pending legal-status Critical Current

Links

JP2011517954A 2008-07-18 2009-07-17 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置 Pending JP2011528332A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08160761.6 2008-07-18
EP08162486 2008-08-15
EP08162486.8 2008-08-15
EP08163614 2008-09-03
EP08163614.4 2008-09-03
EP09160448 2009-05-15
EP09160448.8 2009-05-15
PCT/EP2009/059251 WO2010007165A2 (en) 2008-07-18 2009-07-17 Treatment of inflammatory diseases with mammal beta defensins

Publications (2)

Publication Number Publication Date
JP2011528332A JP2011528332A (ja) 2011-11-17
JP2011528332A5 true JP2011528332A5 (enExample) 2012-04-12

Family

ID=41445843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517954A Pending JP2011528332A (ja) 2008-07-18 2009-07-17 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置

Country Status (18)

Country Link
US (1) US20100016232A1 (enExample)
EP (1) EP2320929B1 (enExample)
JP (1) JP2011528332A (enExample)
KR (2) KR20110044863A (enExample)
CN (1) CN102159232A (enExample)
AP (1) AP2011005537A0 (enExample)
AR (1) AR072524A1 (enExample)
AU (1) AU2009272680A1 (enExample)
BR (1) BRPI0915780A2 (enExample)
CA (1) CA2730674A1 (enExample)
CL (1) CL2011000098A1 (enExample)
EA (1) EA201170218A1 (enExample)
IL (1) IL210714A0 (enExample)
MX (1) MX2011000569A (enExample)
NZ (1) NZ590466A (enExample)
TW (1) TW201004641A (enExample)
WO (1) WO2010007165A2 (enExample)
ZA (1) ZA201100462B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232248B2 (en) * 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
CN102247591A (zh) * 2008-07-18 2011-11-23 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗
AU2011239466B2 (en) 2010-04-15 2015-01-22 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -N-acetylglucosamine nanofibers
KR101257228B1 (ko) * 2010-06-16 2013-04-29 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
MX356877B (es) * 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
US9217021B2 (en) 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
JP6151981B2 (ja) * 2013-06-18 2017-06-21 一般社団法人健康科学リソースセンター 関節リウマチ患者における生物学的製剤の有効性の予測方法
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
BR112018071972A2 (pt) 2016-04-29 2019-02-26 Defensin Therapeutics Aps métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos.
US11413328B2 (en) * 2016-12-13 2022-08-16 Novozymes A/S Methods for treating inflammatory conditions of the lungs
KR102631542B1 (ko) 2018-03-14 2024-02-01 서울대학교산학협력단 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도
KR102631543B1 (ko) * 2018-03-14 2024-02-01 서울대학교산학협력단 세포 투과능 및 근육 재생능을 가지는 이중 기능성 펩타이드 및 이의 용도
WO2020046002A1 (ko) * 2018-08-31 2020-03-05 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR102244161B1 (ko) 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR20240138109A (ko) 2022-01-28 2024-09-20 존슨 앤드 존슨 컨수머 인코포레이티드 아토피성 피부염을 예측하는 바이오마커
EP4504160A1 (en) 2022-04-04 2025-02-12 Kenvue Brands LLC Window of opportunity skin treatment regimen and composition for preventing the onset of or treating atopic dermatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2003288507A1 (en) * 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
CA2704726A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a defensin peptide as a therapeutic agent
US8232248B2 (en) * 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
CN102247591A (zh) * 2008-07-18 2011-11-23 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗

Similar Documents

Publication Publication Date Title
JP2014506321A5 (enExample)
NZ590466A (en) Treatment of inflammatory diseases with mammal beta defensins
JP2014527040A5 (enExample)
JP2015517489A5 (enExample)
JP2010505418A5 (enExample)
JP2012518420A5 (enExample)
HRP20171176T1 (hr) C5ar antagonisti
JP2014516945A5 (enExample)
EP2824111A3 (en) Anti-C5A Antibodies and Methods for Using the Antibodies
JP2009526756A5 (enExample)
HRP20220250T1 (hr) Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
MX2010001400A (es) Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas.
EA035973B9 (en) Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same
JP2010162017A5 (enExample)
JP2010273685A5 (enExample)
BR112014015142A2 (pt) di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios
JP2014510082A5 (enExample)
JP2020522244A5 (enExample)
WO2013048214A3 (en) Novel heterocyclic derivatives and their uses
JP2010515682A5 (enExample)
WO2012038980A3 (en) Fused tricyclic compounds as adenosine receptor antagonist
JP2010526153A5 (enExample)
JP2013543499A5 (enExample)
JP2015524413A5 (enExample)
JP2016540749A5 (enExample)